Every material Form 8-K Cingulate Inc. has filed with the SEC since July 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cingulate Inc. amended the employment agreement of Matthew N. Brams, its Executive Vice President and Chief Medical Officer, on September 30, 2026. The amendment extends the trial period for his full-time employment from September 30, 2026 to December 31, 2026. This is an administrative change to an executive's employment terms and does not disclose any financial results or new compensation figures.
Amendment No. 2 to the employment agreement between Cingulate Therapeutics LLC and Matthew N. Brams was entered into on September 30, 2026, effective January 1, 2026 for the underlying agreement.
The trial period for Mr. Brams' full-time employment was extended from September 30, 2026 to December 31, 2026.
The full amendment is filed as Exhibit 10.1 to the 8-K.
Cingulate reported a second-quarter 2026 net loss of $5.9 million, up from $5.0 million a year earlier, as selling, general and administrative expenses rose 101.5% to $3.9 million on commercial readiness spending. The company said its $28.4 million in cash as of June 30, 2026 should fund operations into mid-2027, but the FDA issued a Complete Response Letter for CTx-1301 on June 1, 2026, and resubmission of the NDA depends on finishing manufacturing work.
Q2 2026 net loss was $5.9 million, compared with $5.0 million in Q2 2025
SG&A expenses were $3.9 million, up 101.5%, driven by commercial readiness build-out
R&D expenses fell 44.9% to $1.5 million in the quarter
Cash and cash equivalents were $28.4 million at June 30, 2026, with runway into mid-2027
Cingulate's Board decided on July 17, 2026 to eliminate the Chief Legal Officer position, and Nilay Patel will leave as an officer effective August 3, 2026. The company said the departure is a termination without cause under his existing employment agreement and that it does not plan to hire a replacement.
Board decision to eliminate the Chief Legal Officer role made July 17, 2026
Nilay Patel's last day as an officer is August 3, 2026, described as termination without cause
No replacement planned for the Chief Legal Officer role
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cingulate Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →